NO20006091L - Humant protein C-polypeptid - Google Patents

Humant protein C-polypeptid

Info

Publication number
NO20006091L
NO20006091L NO20006091A NO20006091A NO20006091L NO 20006091 L NO20006091 L NO 20006091L NO 20006091 A NO20006091 A NO 20006091A NO 20006091 A NO20006091 A NO 20006091A NO 20006091 L NO20006091 L NO 20006091L
Authority
NO
Norway
Prior art keywords
polypeptide
human protein
isolated
disorders
predispose
Prior art date
Application number
NO20006091A
Other languages
English (en)
Other versions
NO20006091D0 (no
Inventor
Lihua Huang
Ralph Meridith Riggin
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of NO20006091D0 publication Critical patent/NO20006091D0/no
Publication of NO20006091L publication Critical patent/NO20006091L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6464—Protein C (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Et isolert, humant protein C-polypeptid med avkortet tung kjede, er beskrevet. Dette isolerte polypeptid bibeholder den biologiske aktivitet av villtypehumant protein C. Dette polypeptid vil være nyttig ved behandling av vaskulære, okklusive lidelser, hyperkoagulerbare tilstander, trombotiske lidelser og sykdomstilstander som pre-disponerer for trombose.
NO20006091A 1998-06-01 2000-11-30 Humant protein C-polypeptid NO20006091L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8758598P 1998-06-01 1998-06-01
PCT/US1999/011969 WO1999063070A1 (en) 1998-06-01 1999-06-01 Human protein c polypeptide

Publications (2)

Publication Number Publication Date
NO20006091D0 NO20006091D0 (no) 2000-11-30
NO20006091L true NO20006091L (no) 2001-01-31

Family

ID=22206075

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20006091A NO20006091L (no) 1998-06-01 2000-11-30 Humant protein C-polypeptid

Country Status (25)

Country Link
US (1) US20040038288A1 (no)
EP (1) EP1084235A4 (no)
JP (1) JP2002517191A (no)
KR (1) KR20010043941A (no)
CN (1) CN1303428A (no)
AR (1) AR020082A1 (no)
AU (1) AU4409399A (no)
BR (1) BR9910858A (no)
CA (1) CA2330171A1 (no)
CO (1) CO5070672A1 (no)
DZ (1) DZ2803A1 (no)
EA (1) EA200001254A1 (no)
HR (1) HRP20000826A2 (no)
HU (1) HUP0102014A3 (no)
ID (1) ID27282A (no)
IL (1) IL139595A0 (no)
NO (1) NO20006091L (no)
NZ (1) NZ507982A (no)
PE (1) PE20000561A1 (no)
PL (1) PL344349A1 (no)
SK (1) SK17502000A3 (no)
SV (1) SV1999000067A (no)
TR (1) TR200003552T2 (no)
WO (1) WO1999063070A1 (no)
ZA (1) ZA200006647B (no)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006025995A2 (en) * 2004-07-27 2006-03-09 The Regents Of The University Of California Compositions and methods using md-2 mutants and chimeric proteins
CN108159399B (zh) * 2017-12-29 2020-07-24 华中科技大学同济医学院附属同济医院 一种凝血蛋白酶aPC在防治糖尿病心肌病药物中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2728240B2 (ja) * 1988-07-26 1998-03-18 ヘキスト薬品工業株式会社 ヒトプロテインｃ変異体及びその製造方法
ES2113878T3 (es) * 1989-12-29 1998-05-16 Zymogenetics Inc Proteina c hibrida.
WO1991012320A1 (en) * 1990-02-09 1991-08-22 Zymogenetics, Inc. Activated protein c with truncated light chain
JPH0564588A (ja) * 1991-08-14 1993-03-19 Teijin Ltd 短い重鎖を有するヒトプロテインｃおよび活性化ヒトプロテインｃ

Also Published As

Publication number Publication date
HUP0102014A2 (hu) 2001-10-28
EP1084235A1 (en) 2001-03-21
HUP0102014A3 (en) 2003-09-29
CO5070672A1 (es) 2001-08-28
PL344349A1 (en) 2001-11-05
EA200001254A1 (ru) 2001-06-25
US20040038288A1 (en) 2004-02-26
SK17502000A3 (sk) 2001-09-11
TR200003552T2 (tr) 2001-05-21
DZ2803A1 (fr) 2003-12-01
CN1303428A (zh) 2001-07-11
ZA200006647B (en) 2001-11-15
WO1999063070A1 (en) 1999-12-09
KR20010043941A (ko) 2001-05-25
AU4409399A (en) 1999-12-20
NZ507982A (en) 2004-01-30
SV1999000067A (es) 2000-07-06
EP1084235A4 (en) 2002-03-27
IL139595A0 (en) 2002-02-10
JP2002517191A (ja) 2002-06-18
HRP20000826A2 (en) 2001-10-31
AR020082A1 (es) 2002-04-10
ID27282A (id) 2001-03-22
BR9910858A (pt) 2001-03-06
CA2330171A1 (en) 1999-12-09
NO20006091D0 (no) 2000-11-30
PE20000561A1 (es) 2000-07-22

Similar Documents

Publication Publication Date Title
TR199801390T2 (xx) Tromboz tedavisinde kullan�lacak p�ht�la�may� �nleyici maddeler
DE60042137D1 (de) Rekombinante alpha-l-iduronidase und behandlung von durch diese hervorgerufene mangelerkrankungen
DE60233955D1 (de) Spezifische bindungsmittel von human angiopoietin-2
DE69434651D1 (de) Bmp-12, bmp-13 und diese enthaltende sehne-induzierende zusammensetzungen
DE60045034D1 (de) Überstände von mesenchymstammzellen zur vorbeugung und behandlung von immunantworten in transplantationen
SE8902532D0 (sv) Bestaemning av plasmaproteiner
ATE279181T1 (de) Verwendung von 5ht-6 antagonisten zur behandlung adhd
DE3579113D1 (de) Zusammensetzungen zur milderung, behandlung und bestimmungung von arthritschen krankheiten und aehnlichen zustaenden.
DE69929681D1 (de) Mesenchymale stammzellen für die prävention und behandlung von immunantworten bei transplantationen
DE60229406D1 (de) Verfahren zur behandlung oder verhinderung von vaskulärer entzündung mit sterol-absorbierungs- inhibitor(en)
ATE275411T1 (de) Verwendung von phyllanthus zur behandlung von chronisch entzündlichen und fibrotischen prozessen
DE69932845D1 (de) Methoden zur quantifizierung von hla-dr und cd11b
PT948604E (pt) Produtos e metodos relacionados com pyk2
DE69838509D1 (de) Verwendung von rekombinanten menschlichen uteroglobin zur behandlung von fibrotischen krankheitszuständen
DE69033511D1 (de) Verfahren zum Nachweis von Knochen- und anderen Bindegewebeerkrankungen in Menschen und Tieren
BR9007115A (pt) Novo trombolitico
NO20006091L (no) Humant protein C-polypeptid
ATE313561T1 (de) Vgf polypeptide und verfahren zur behandlung von vgf-erkrankungen
DE60108076D1 (de) Protein c derivate
DE69932922D1 (de) Verwendung von alkansäuren-enthaltenden zusammensetzungen zur behandlung von nagelpilz-erkrankungen
EA200401390A1 (ru) N-ацетилглюкозамин-6-фосфатдеацетилаза человека, взаимодействующая с каспазой-8, и способы ее применения
DE60118769D1 (de) Verwendung von langem pentraxin ptx3 zur behanlung von durch geänderte aktivität des fgf-2 wachstumsfaktors hervorgerufene krankheiten
DE68920757D1 (de) Lysyl-Oxidase-Inhibitoren.
ATE312914T1 (de) Rdgb-proteine
WO2001036462A3 (en) Protein c derivatives

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application